Financhill
Sell
30

CCEL Quote, Financials, Valuation and Earnings

Last price:
$3.45
Seasonality move :
5.78%
Day range:
$3.41 - $3.53
52-week range:
$3.10 - $8.79
Dividend yield:
19.06%
P/E ratio:
498.00x
P/S ratio:
0.87x
P/B ratio:
--
Volume:
7.4K
Avg. volume:
12.3K
1-year change:
-55.19%
Market cap:
$27.5M
Revenue:
$32M
EPS (TTM):
-$0.06

Analysts' Opinion

  • Consensus Rating
    Cryo-Cell International, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $8.50, Cryo-Cell International, Inc. has an estimated upside of 149.27% from its current price of $3.41.
  • Price Target Downside
    According to analysts, the lowest downside price target is $8.50 representing 100% downside risk from its current price of $3.41.

Fair Value

  • According to the consensus of 1 analyst, Cryo-Cell International, Inc. has 149.27% upside to fair value with a price target of $8.50 per share.

CCEL vs. S&P 500

  • Over the past 5 trading days, Cryo-Cell International, Inc. has overperformed the S&P 500 by 0.21% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Cryo-Cell International, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Cryo-Cell International, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Cryo-Cell International, Inc. reported revenues of $7.8M.

Earnings Growth

  • Cryo-Cell International, Inc. earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Cryo-Cell International, Inc. reported earnings per share of $0.09.
Enterprise value:
36.8M
EV / Invested capital:
--
Price / LTM sales:
0.87x
EV / EBIT:
8.52x
EV / Revenue:
1.16x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.96x
Price / Operating cash flow:
4.48x
Enterprise value / EBITDA:
6.46x
Gross Profit (TTM):
$23.7M
Return On Assets:
-0.74%
Net Income Margin (TTM):
-1.49%
Return On Equity:
--
Return On Invested Capital:
-20.01%
Operating Margin:
24.29%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-08-31 2024-08-31 2025-08-31 2024-08-31 2025-08-31
Income Statement
Revenue $31.2M $31.8M $31.7M $8.1M $7.8M
Gross Profit $21.6M $22.9M $23.7M $5.7M $5.8M
Operating Income $4.4M -$139.4K $4.3M $1.4M $1.9M
EBITDA $6.1M $952.6K $5.7M $1.7M $2.3M
Diluted EPS $0.30 -$1.08 -$0.06 $0.13 $0.09
Period Ending 2021-08-31 2022-08-31 2023-08-31 2024-08-31 2025-08-31
Balance Sheet
Current Assets $14.9M $11.1M $9.9M $10.7M $11.7M
Total Assets $59.4M $66.8M $69.8M $62.9M $63.2M
Current Liabilities $19.9M $23.6M $18.6M $17.4M $18.5M
Total Liabilities $54.6M $69.2M $69.8M $72.5M $78M
Total Equity $4.8M -$2.4M -$16.2K -$9.6M -$14.8M
Total Debt $3.4M $9.1M $9.5M $9.1M $9M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-08-31 2024-08-31 2025-08-31 2024-08-31 2025-08-31
Cash Flow Statement
Cash Flow Operations $8M $7.2M $6.4M $2.4M $2.5M
Cash From Investing -$4.2M -$5.7M -$1.8M -$665.6K $1.1M
Cash From Financing -$6.1M -$1.8M -$4.5M -$2M -$3.5M
Free Cash Flow $7.4M $3.1M $6.2M $2.3M $2.5M
CCEL
Sector
Market Cap
$27.5M
$25.9M
Price % of 52-Week High
38.79%
51.6%
Dividend Yield
19.06%
0%
Shareholder Yield
0.78%
-1.66%
1-Year Price Total Return
-55.19%
-18.99%
Beta (5-Year)
0.689
0.485
Dividend yield:
19.06%
Annualized payout:
$0.25
Payout ratio:
3067.58%
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $3.41
200-day SMA
Sell
Level $4.59
Bollinger Bands (100)
Sell
Level 3.7 - 4.6
Chaikin Money Flow
Buy
Level 3.5M
20-day SMA
Sell
Level $3.46
Relative Strength Index (RSI14)
Sell
Level 40.15
ADX Line
Buy
Level 14.25
Williams %R
Neutral
Level -70.1923
50-day SMA
Sell
Level $3.77
MACD (12, 26)
Sell
Level -0.11
25-day Aroon Oscillator
Sell
Level -16
On Balance Volume
Neutral
Level 5.9M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.3504)
Sell
CA Score (Annual)
Level (-3.1744)
Buy
Beneish M-Score (Annual)
Level (-2.7553)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-6.6063)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage, and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded in 1989 and is headquartered in Oldsmar, FL.

Stock Forecast FAQ

In the current month, CCEL has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CCEL average analyst price target in the past 3 months is $8.50.

  • Where Will Cryo-Cell International, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Cryo-Cell International, Inc. share price will rise to $8.50 per share over the next 12 months.

  • What Do Analysts Say About Cryo-Cell International, Inc.?

    Analysts are divided on their view about Cryo-Cell International, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cryo-Cell International, Inc. is a Sell and believe this share price will drop from its current level to $8.50.

  • What Is Cryo-Cell International, Inc.'s Price Target?

    The price target for Cryo-Cell International, Inc. over the next 1-year time period is forecast to be $8.50 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is CCEL A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Cryo-Cell International, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.

  • How Can I Buy Shares Of CCEL?

    You can purchase shares of Cryo-Cell International, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cryo-Cell International, Inc. shares.

  • What Is The Cryo-Cell International, Inc. Share Price Today?

    Cryo-Cell International, Inc. was last trading at $3.45 per share. This represents the most recent stock quote for Cryo-Cell International, Inc.. Yesterday, Cryo-Cell International, Inc. closed at $3.41 per share.

  • How To Buy Cryo-Cell International, Inc. Stock Online?

    In order to purchase Cryo-Cell International, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did AMD Stock Go Up?
Why Did AMD Stock Go Up?

Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…

Will Data Centers Be In Space?
Will Data Centers Be In Space?

With demand for data centers seemingly growing by the day,…

Why Did SoundHound AI Stock Go Up?
Why Did SoundHound AI Stock Go Up?

SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
57
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Sell
47
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
56
INTC alert for Jan 24

Intel Corp. [INTC] is down 17.01% over the past day.

Buy
64
BNR alert for Jan 24

Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.

Sell
19
APGE alert for Jan 24

Apogee Therapeutics, Inc. [APGE] is down 12.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock